| 翻訳と辞書 |
| Cambrex Corporation ： ウィキペディア英語版 |
Cambrex Corporation
Cambrex Corporation is a global, innovative life sciences company that provides products and services to accelerate the development and commercialization of small molecule active pharmaceutical ingredients (APIs).
Cambrex has cGMP manufacturing facilities in the US (Charles City, IA), Europe (Karlskoga, Sweden, Milan, Italy and Hyderabad, India, and R&D centers in Tallinn, Estonia, Wiesbaden, Germany). The headquarters are located in East Rutherford, NJ.
In 2007, Cambrex divested their biologics business to Lonza to focus on small molecule APIs.
==History==
Cambrex was founded in 1981, when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco. Through multiple acquisitions during the late 1990s, Cambrex entered the bioscience and the chiral enzymatic catalyst markets. In 1998, Cambrex was listed on the NYSE. Cambrex acquired two contract biopharmaceutical manufacturing facilities, in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, Cambrex decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP, now known as Cambrex IEP. In 2014, Cambrex acquired Zenara Pharma to enhance its drug product formulation capabilities, including Nicotine Replacement Therapy products.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Cambrex Corporation」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|